Polycystic Ovary Syndrome in Type 1 Diabetes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-45
SponsorFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

About this trial

BACKGROUND Functional ovarian hyperandrogenism, including the polycystic ovary syndrome (PCOS), is very prevalent in women with type 1 diabetes (T1D). The pathogenic mechanisms of this association remain unclear.

HYPOTHESIS Individual factors expose or protect women with T1D to/from the development of androgen excess and PCOS. Such androgen excess in women with T1D may increase their cardiometabolic risk.

MAIN OBJECTIVE Unveiling the pathogenic mechanisms behind functional hyperandrogenism in women with T1D from a sex/gender-medicine and sexual dimorphism perspective.

MATERIAL AND METHOS We have designed a cross-sectional comparative clinical study, including 5 groups of study subjects with 12 participans per group:

i) Women with T1D \& PCOS. ii) Women with T1D without PCOS. iii) Men with T1D and normal gonadal function. iv) Women with PCOS without diabetes mellitus v) Non-hyperandrogenic control women without T1D. All groups will show similar age and body mass index. T1D groups will be matched for duration of disease.

OUTCOMES 1.1 Insulin sensitivity (hyperinsulinaemic euglycaemic clamping). 1.2 Body composition (dual-energy x-ray absorptiometry, bioelectrical impedance analysis \& sonographic studies).

1.3 Ovarian and adrenal steroidogenesis. 2.1 Differential pattern in genetic variants related with insulin signalling and response, inflammation, adiposity, gonadal function, steroidogenesis, and PCOS itself by whole exome sequencing.

2.2 Microbiopsy studies in deep subcutaneous adipose tissue and skeletal muscle tissue: 2.2.1 Differential DNA methylation patterns in genes associated with PCOS. 2.2.2 Differential transcriptomic pattern in genes associated with PCOS.

2.2.3 Differential proteomic patterns in adipose and muscle tissues. 3. Interaction between T1D and PCOS on parameters of metabolic control (intersticial blood glucose monitoring) and morbidities associated with T1D itself.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Non--hyperandrogenic women with type 1 diabetes * Premenopausal women between 18 and 45 years old.

Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency.

Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion).

Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry.

Disqualifiers

Honeymoon period of T1D.

Pregnancy or lactation.

Thyroid hormone dysfunction or hyperprolactinaemia.

Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism.

Trial population

Premenopausal adult women with type 1 diabetes mellitus presenting with or without polycystic ovary syndrome.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

  • Type 1 diabetes mellitus

    Other intervention

    A diagnosis of type 1a diabetes mellitus

  • Elevated circulating androgen levels

    Other intervention

    Androgen excess exposition due to a diagnosis of polycystic syndrome or male sex

  • Sex dimorphism

    Other intervention

    Effects of sex on outcomes measures

Treatment groups

60 Participants
are divided into 5 treatment groups
Group A: Non--hyperandrogenic women with type 1 diabetes2 interventions
Group B: Women with type 1 diabetes and polycystic ovary syndrome3 interventions
Group C: Men with T1D and normal gonadal function of similar age, BMI, and duration of diabetes.3 interventions
Group D: Women with PCOS of similar age and BMI.2 interventions
Group E: Non-hyperandrogenic control women with regular menses of similar age and BMI1 intervention

Trial outcomes

Primary outcomes

1

Differences in insulin sensitivity between study subgroups

Study of sensitivity to insulin action by hyperinsulinaemic euglycaemic clamp. Clamping will be conducted in the follicular phase fo women's study participants. In this protocol free fatty acids will be also determined in stored samples.

Time frame
At baseline
2

Fat mass percentage

Body composition studies: Fat mass percentage with respect to total body weight. Methodology: Bioelectrical impedance analysis by Monitor VitalScan Medeia® System device (United States, CA).

Time frame
At baseline
3

Phase angle 50 KHz

Methodology: Bioelectrical impedance analysis by Monitor VitalScan Medeia® System device (United States, CA).

Time frame
At baseline
4

Peritoneum-vertebral column fat thickness

Ultrasound assessment of fat compartments, determined using Toshiba Nemio ZG SSA-580ª ultrasound equipment (Toshiba Medical Systems, S.A., Alcobendas, Madrid) following the protocol previously validated and reported by our research group (PMID: 23386652).

Time frame
At baseline

Secondary outcomes

1

Identify genomic variants in genes/proteins related to insulin signalling and action, adiposity, inflammation, steroidogenesis, and PCOS itself

This approach will permit a detailed characterization of all the genetic variants present in the coding portion of the human genome, covering not only genes already identified to be associated with PCOS, but also other genes related to the pathophysiology of PCOS in women with T1D. Bioinformatic analysis of WES will be focused on genes that have been linked to PCOS and functional hyperandrogenism in populations of European ancestry in previous candidate gene studies and genome wide association studies, leaving open the possibility of analyzing other genes of interest depending on the results obtained in other studies of the project and the data published by other groups. Genomic DNA will be isolated from peripheral bood with the FlexiGene DNA Qiagen kit and submitted to an external biotech company (Macrogen Spain) for conducting these studies. Genomic DNA will be isolated from peripheral blood with the FlexiGene DNA Qiagen kit and submitted to an external biotech company.

Time frame
At baseline
2

Description of differential DNA methylation patterns in deep subcutaneous adipose and skeletal muscle tissues (Epigenomics)

Oxford Nanopore sequencing enables direct detection of methylated cytosines from isolated genomic DNA without the need for bisulphite conversion. The Adaptive Sampling RRMS panel (Reduced Representation Methylation Sequencing) protocol enables to target the regions of human genome highly enriched for CpG sites, including a total number of 7-8M CpGs, and multiplexing up to 4 samples on a single PromethION flow cell.

Time frame
At baseline
3

Description of differential gene expression profiles in adipose and muscle tissues (Transcriptomics)

RNA from adipose and muscle will be isolated using the Fatty Tissue and Total RNA Purification kits (Norgen Biotek). RNA quantity and quality shall be evaluated with the Qubit fluorimeter and Agilent Bioanalyzer. RNAseq libraries will be prepared following the protocol included in the Illumina® Stranded Total RNA Prep, Ligation with Ribo-Zero Plus kit. Sequencing will be performed using an Illumina NovaSeqXPlus (1x100bp) with \>40M reads/sample. Targeted expression of selected genes (chosen according RNAseq results) will be assessed by real-time qPCR in a LightCycler480 with products from AnyGenes company.

Time frame
At baseline
4

Description of differential proteomic profiles in adipose and muscle tissue (Proteomics)

Comparative proteome analysis with isobaric tandem mass tag (TMT). Samples will be processed according to the protocol described in Carmona L. et al. (PMID: 37171157) on S-Trap columns. The resulting peptides will be labelled with TMT18plex labels according to the manufacturer's instructions (Thermo Scientific). The labelled peptides shall be separated on an Ultimate 3000 nanochromatograph on a C18 reverse phase column.

Time frame
At baseline

Other outcomes

1

Insulin requirements/day adjusted for weight

To evaluate the interaction between T1D and PCOS on parameters of metabolic control and morbidities associated with T1D itself.

Time frame
At baseline
2

Time in range

Interstitial blood glucose monitoring: time in range \[between 70 and 180 mg/dl (%)\]

Time frame
Since 4 weeks prior to inclusion in study
3

Ambulatory blood pressure

Blood pressure determined according to 24-hour ambulatory blood pressure monitoring

Time frame
At baseline
4

Subclinical atherosclerosis: Differences in carotid intimomedial thickness between study subgroups

Imaging will be conducted using a high-resolution 7-15 MHz phased-array transducer (EPIQ 5, Philips Healthcare, Bothell, WA, USA) by the same trained operator in all study participants. This operator will be blinded to the women's features and their group allocation. Under controlled light and temperature conditions, studies will be performed by positioning the women in a supine position with a 35-degree incline of the head and torso, and a 45 degrees right-turn or left-turn, respectively, of the head. The left and right common carotid arteries will be explored in B-mode in longitudinal and transversal planes, to rule out the presence of plaque that might interfere with cIMT measurements. The posterior carotid wall at 1 cm of the common carotid bulb will be imaged and cIMT estimated by visual assessment (average of five manual measurements) of the distance between the lumen/intima and intima/adventitia interphases in longitudinal frames acquired during arterial diastole.

Time frame
At baseline

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Lead sponsor

Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders

Collaborator

University of Alcala

Collaborator